NEW YORK – Allelica said on Thursday that Illumina is licensing its software for developing polygenic risk scores (PRS).
The agreement allows Illumina to offer Allelica's PRS technology to its customers via its Illumina Connected Analytics bioinformatics software platform, enabling them to identify individuals with a high genetic risk of developing life-threatening diseases.
Allelica said its platform streamlines the polygenic risk scoring process, from imputation and development to validation across multiple ancestries and for a range of disorders.
"Integrating the first PRS module into the Illumina Connected Analytics platform will help empower researchers to mature the field of polygenic risk score utility and help transform the way we think about human health," Ashley Van Zeeland, head of Illumina Open Innovation, said in a statement.
The collaboration also includes codevelopment of an Illumina Infinium genotyping array that includes curated content specific for PRS predictions.
Allelica also recently partnered with a Yale University researcher to develop PRS related to neuropsychiatric disorders.